Pyoderma Gangrenosum (PG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Pyoderma Gangrenosum (PG) Market Outlook

Thelansis’s “Pyoderma Gangrenosum (PG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pyoderma Gangrenosum treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pyoderma Gangrenosum (PG) Overview

Pyoderma gangrenosum (PG) is a rare skin disease characterized by the formation of ulcers on the body, particularly in the pre-tibial area, which often results in unsightly scar tissue. Diagnosis of PG relies primarily on clinical observation since no specific markers are detectable through blood tests or tissue analysis. The underlying causes and mechanisms of PG are not well understood, and current treatments are based on empirical evidence rather than targeted approaches. PG is characterized by recurring painful ulcers on the skin, most commonly found on the pre-tibial region but can appear anywhere on the body, including the trunk, head and neck, upper limbs, and genitalia. Multiple ulcers can co-occur on different anatomical sites, and PG may also manifest in the peristomal area, accounting for a significant proportion of chronic parastomal ulcers. About 50% of PG cases are associated with systemic diseases, while the remaining cases are idiopathic. Inflammatory bowel disease, rheumatoid arthritis, and hematological malignancies are the most commonly linked diseases. There are four distinct classes of PG: ulcerative, pustular, bullous, and vegetative. These classifications aid in recognizing different disease presentations, although variants can overlap. Ulcerative PG, or classic PG, is the most common form, exhibiting the previously described symptoms, and is frequently associated with inflammatory bowel disease, arthritis, or monoclonal gammopathies. Pustular PG is a more superficial variant primarily linked to inflammatory bowel disease. Bullous PG is another superficial form characterized by painful blisters, predominantly on the upper limbs and face, often associated with hematological malignancies. Vegetative PG is usually less aggressive than other variants, progressing slowly with fewer symptoms and generally responding well to milder treatments. Peristomal PG may develop after ileostomy or colostomy in individuals with inflammatory bowel disease, possibly due to the surgical procedure or subsequent irritation by the stoma apparatus or fecal leakage. Currently, there is no specific or targeted therapy for PG, and treatment approaches rely heavily on empirical evidence, considering factors such as the severity and extent of ulceration, associated diseases, and patient characteristics. The primary goals of treatment are to reduce inflammation and pain in the lesions and promote healing.

• The prevalence of PG, standardized for age and sex, is 5.8 cases per 100,000 adults. Adjusted prevalence rates indicate a nearly two-fold higher occurrence in women (7.1 cases per 100,000) compared to men (4.4 cases per 100,000).
• The highest standardized prevalence is observed in individuals aged 70 to 79 (9.8 cases per 100,000), with patients aged 50 or older accounting for nearly 70% of all PG cases.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: